Vimian Group AB (VIMIAN) AI Stock Analysis

• Market Cap: kr16.16B
• Dividend Yield: N/A
• Average Volume (3M): 772.80K
• Price to Earnings (P/E): 45.7
• Beta (1Y): 0.80
• Revenue Growth: 17.13%
• EPS Growth: N/A
• Country: SE
• Employees: 1,200
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.21
• Shares Outstanding: 525,964,540
• 10 Day Avg. Volume: 366,844
• 30 Day Avg. Volume: 772,803
• PEG Ratio: 1.13
• Price to Book (P/B): 2.49
• Price to Sales (P/S): 4.65
• P/FCF Ratio: 39.67
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr32.63
• Price Target Upside: 6.21% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: kr35.00 ▲(13.93% Upside)

The score is primarily supported by stable financial performance and improving technical momentum (price above key moving averages with positive MACD). This is meaningfully offset by a high valuation (P/E 48.48) and weaker profitability/returns with declining free cash flow growth, which raise execution risk.

Positive Factors

High gross margins

Sustained gross margin near 69% and stable operating margins indicate durable unit economics and pricing power in core veterinary products. This provides long-term flexibility to invest in R&D and distribution while supporting margin resilience across cycles.

Diversified revenue streams

Multiple business lines—diagnostics, therapeutics and digital platforms—reduce dependence on any single product and support cross-selling to veterinary customers. Structural diversification helps sustain revenue under shifting market demands and supports steady long-term growth.

Balanced capital structure

Moderate leverage and a healthy equity base limit financial risk and preserve borrowing capacity. This balance supports strategic investments, acquisitions, or R&D spending without jeopardizing solvency, enhancing long-term operational and financial flexibility.

Negative Factors

Weak net profitability

Low net margin and meager ROE constrain retained earnings and shareholder returns, limiting the company’s ability to self-fund growth and lowering resilience to cost shocks. Persistent weak profitability raises execution risk over multi-quarter horizons.

Declining free cash flow growth

Negative FCF growth signals reduced cash available for reinvestment, dividends, or debt reduction. Over several quarters this can force tougher capital-allocation choices, hamper funding for innovation or expansion, and increase reliance on external financing.

Modest revenue growth

Single-digit top-line expansion suggests limited market penetration or slower demand compared with high-growth peers. Persistently modest revenue growth constrains scale benefits, slows margin improvement, and makes long-term return generation more dependent on cost cuts or M&A.

Vimian Group AB Business Overview & Revenue Model

Company Description

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. The company was incorporated in 2020 and is headquartered in Stockholm, Sweden.

How the Company Makes Money

Vimian generates revenue through multiple streams, primarily by selling veterinary diagnostic products, pharmaceuticals, and digital solutions to veterinary clinics and animal health professionals. The company leverages its expertise in the veterinary sector to develop proprietary technologies and solutions that meet the evolving needs of the market. Additionally, Vimian benefits from strategic partnerships with other organizations in the animal health industry, enabling them to expand their product offerings and reach a broader customer base. The combination of direct sales, partnerships, and a focus on innovation contributes significantly to Vimian's earnings.

Vimian Group AB Financial Statement Overview

Summary

Vimian Group AB demonstrates solid revenue growth and operational efficiency, with strong gross margins and stable EBIT/EBITDA margins. The balance sheet is stable with moderate leverage, but returns on equity could be improved. Cash flow generation is adequate, though recent declines in free cash flow growth warrant attention. Overall, the company is financially stable with opportunities for enhanced profitability and cash flow management.

Income Statement

Vimian Group AB shows a consistent revenue growth trajectory with a TTM revenue growth rate of 4.12%. The gross profit margin remains strong at 68.71%, indicating efficient cost management. However, the net profit margin is relatively low at 5.61%, suggesting room for improvement in profitability. EBIT and EBITDA margins are stable, reflecting solid operational performance.

Balance Sheet

The company's debt-to-equity ratio is moderate at 0.43, indicating a balanced approach to leveraging. Return on equity is modest at 3.31%, suggesting limited returns on shareholders' investments. The equity ratio is healthy, reflecting a strong capital structure. Overall, the balance sheet shows stability but highlights the need for improved returns.

Cash Flow

Operating cash flow to net income ratio is 0.85, indicating good cash generation relative to earnings. However, free cash flow growth is negative at -7.67%, pointing to potential cash flow challenges. The free cash flow to net income ratio is strong at 0.84, suggesting efficient cash conversion despite recent declines.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	421.00M	374.80M	331.73M	281.31M	173.35M	137.75M
Gross Profit	288.90M	258.30M	229.43M	193.99M	122.85M	95.52M
EBITDA	96.70M	82.80M	69.19M	39.20M	36.16M	65.16M
Net Income	31.30M	18.50M	9.84M	-7.20M	6.59M	52.79M
Balance Sheet
Total Assets	1.12B	1.11B	973.68M	923.56M	640.72M	456.29M
Cash, Cash Equivalents and Short-Term Investments	51.30M	64.80M	37.50M	42.19M	55.11M	29.66M
Total Debt	270.00M	233.60M	313.80M	220.96M	180.37M	85.91M
Total Liabilities	426.80M	403.30M	446.97M	442.06M	282.08M	182.05M
Stockholders Equity	686.10M	699.90M	526.37M	481.81M	357.41M	224.02M
Cash Flow
Free Cash Flow	62.00M	43.90M	-43.48M	15.01M	4.52M	-793.00K
Operating Cash Flow	74.50M	58.10M	-28.58M	25.31M	16.01M	4.80M
Investing Cash Flow	-64.80M	-76.00M	-77.68M	-188.53M	-115.00M	-105.24M
Financing Cash Flow	4.40M	44.80M	100.55M	150.23M	123.94M	118.57M

Vimian Group AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 30.72
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VIMIAN, the sentiment is Negative. The current price of 30.72 is above the 20-day moving average (MA) of 30.47, above the 50-day MA of 30.15, and below the 200-day MA of 34.41, indicating a neutral trend. The MACD of 0.47 indicates Negative momentum. The RSI at 50.59 is Neutral, neither overbought nor oversold. The STOCH value of 35.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:VIMIAN.

Vimian Group AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VITR	71 Outperform	kr18.03B	40.87	3.34%	0.80%	-1.29%	―
VIMIAN	64 Neutral	kr16.16B	45.71	4.63%	―	17.13%	―
ALIF.B	64 Neutral	kr18.55B	47.04	7.24%	0.46%	5.14%	236.75%
MCAP	62 Neutral	kr7.90B	39.81	15.16%	―	11.30%	-14.49%
NOLA.B	61 Neutral	kr16.70B	21.17	14.17%	2.48%	0.40%	38.42%
EKTA.B	55 Neutral	kr24.17B	83.02	3.08%	4.25%	-0.90%	-70.95%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Vimian Group AB Corporate Events

Vimian’s Specialty Pharma Chief to Step Down in Spring 2026

Vimian Group AB has announced that Magnus Kjellberg, Head of its Specialty Pharma segment and a long-standing member of the group management team, will step down during spring 2026 to pursue opportunities outside the company. Kjellberg has been credited with helping build Vimian’s global Specialty Pharma platform in animal health, combining acquisition-led and organic growth, and the company emphasizes that the segment is now in a strong position for continued success; CFO Carl-Johan Zetterberg Boudrie will assume the role of interim Head of Specialty Pharma while a search for a permanent successor begins, with a transition period planned to ensure operational continuity and stability for stakeholders.

The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Updates Share Capital and Voting Rights After Incentive Programme Issues

Vimian Group AB has increased its total number of shares and votes following the issuance of new D, E1 2025, E2 2025 and E3 2025 shares under its LTIP 2025/2028 incentive programme and the conversion of a small number of C shares into ordinary shares. As of the last trading day in December 2025, the company has 529,262,637 shares outstanding, comprising several share classes with different voting rights, resulting in a total of 526,294,558.5 votes and reflecting ongoing use of equity-based incentives to align management and employees with shareholder interests while slightly diluting existing shareholders.

The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK39.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Buys Italian Vet Diagnostics Firm I-Vet to Bolster Companion Animal Offering

Vimian Group AB has agreed to acquire I-Vet, a leading Italian provider of reference laboratory services and in-clinic diagnostic solutions for companion animals, which serves some 5,000 veterinary clinics and generates annual revenues of around EUR 5.6 million. The deal, Vimian’s fifth acquisition in 2025, will fold I-Vet into its Diagnostics segment, retain CEO and founder Daniele Franzini at the helm, and is financed with existing cash, underscoring Vimian’s strategy to deepen its footprint in the fast-growing companion animal diagnostics market while having only a marginal impact on earnings per share in 2026.

The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK39.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Issues and Repurchases Additional Shares to Expand 2025 Incentive Program

Vimian Group AB has resolved to issue and subsequently repurchase a total of 596,437 additional class D, E1 2025, E2 2025 and E3 2025 shares as part of its previously approved 2025 long-term incentive program based on hurdle shares and employee stock options. The new shares, subscribed by DNB Carnegie Investment Bank at quota value and immediately repurchased by Vimian for later transfer to program participants, slightly increase share capital while using non-dividend, low-vote share classes and deviating from preferential rights specifically to facilitate broader participation and category changes in the incentive plan, aligning employee and management incentives with shareholder interests without materially diluting control or cash flows for existing investors.

The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK39.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group AB Expands Share Base Through Incentive Program

Vimian Group AB announced an increase in its number of shares and votes due to the issuance of D shares, E1 2025 shares, E2 2025 shares, and E3 2025 shares as part of its incentive program LTIP 2025/2028. This change reflects a strategic move to enhance its market positioning and operational capabilities, potentially impacting stakeholders by increasing the company’s voting power and share distribution.

The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK39.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group Appoints Alireza Tajbakhsh as CEO to Drive Growth

Vimian Group AB has appointed Alireza Tajbakhsh as its new CEO, effective immediately. Tajbakhsh, who has been with Vimian since 2021, previously led the Veterinary Services segment and served as interim Head of the MedTech segment. His leadership is expected to continue driving the company’s strategy of organic and acquisition-driven growth, enhancing its position in the animal health industry. The appointment is seen as a strategic move to strengthen Vimian’s global leadership in animal health niches with unmet medical needs, aiming to improve animal health through science and technology.

The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK33.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group Initiates Share Issuance for LTIP 2025

Vimian Group AB has announced the issuance and repurchase of various classes of shares as part of its long-term incentive program (LTIP 2025). This strategic move, authorized during an Extraordinary General Meeting, aims to enhance employee engagement and align interests with shareholders, potentially strengthening Vimian’s market position and operational focus.

The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group Reports Strong Q3 2025 Performance Amid Leadership Change

Vimian Group AB reported strong financial performance for the third quarter of 2025, with a 19% increase in net revenue to EUR 104.3 million and a 9% organic growth. The company also saw a significant rise in operating profit and EBITA, indicating robust operational efficiency. Notably, the company resolved a legal dispute favorably, securing USD 40.2 million, and announced a leadership change with the appointment of an interim CEO.

The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK37.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group Announces Q3 2025 Interim Report Release

Vimian Group AB announced the release of its Interim Report for the third quarter of 2025, scheduled for October 22. The report will be presented via an audiocast by CFO and interim CEO Carl-Johan Zetterberg Boudrie and Magnus Kjellberg, CEO of the Specialty Pharma segment. This event is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction.

The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK37.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.